121 related articles for article (PubMed ID: 38150820)
1. Impact of the Identification of Nonhuman Genetic Signatures in the Diagnosis and Management of Carcinoma of Unknown Primary.
Barquín García A; Palacios-Zambrano S; Lozano Alarcón F; Paumard-Hernández B; Quiralte Pulido M; Navarro P; Rodríguez L; Salas Villar I; García-Donas J
J Natl Compr Canc Netw; 2023 Dec; 22(1D):e237079. PubMed ID: 38150820
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
[TBL] [Abstract][Full Text] [Related]
3. Supraclavicular lymph node metastases of unknown origin: HPV-typing identifies the primary tumour.
Kuemper C; Burges A; Hillemanns P; Mueller-Egloff S; Lenhard M; Ditsch N; Strauss A
Eur J Cancer Care (Engl); 2009 Nov; 18(6):606-11. PubMed ID: 19549285
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Adenocarcinoma, HPV-independent, Mesonephric Type with Significant Response to Neoadjuvant Chemotherapy].
Kuratsune K; Ueda T; Tajiri R; Tohyama A; Hoshino K; Harada H; Kurita T; Kubo C; Komatsu K; Shiba E; Matsuura Y; Yoshino K
J UOEH; 2024; 46(1):45-51. PubMed ID: 38479874
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Ishikawa M; Shibata T; Iwata T; Nishio S; Takada T; Suzuki S; Horie K; Kudaka W; Kagabu M; Tanikawa M; Kitagawa R; Takekuma M; Kobayashi H; Yaegashi N;
Gynecol Oncol; 2021 Aug; 162(2):292-298. PubMed ID: 34016453
[TBL] [Abstract][Full Text] [Related]
6. Cervical small cell carcinoma frequently presented in multiple high risk HPV infection and often associated with other type of epithelial tumors.
Li P; Ma J; Zhang X; Guo Y; Liu Y; Li X; Zhao D; Wang Z
Diagn Pathol; 2018 May; 13(1):31. PubMed ID: 29788963
[TBL] [Abstract][Full Text] [Related]
7. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.
Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Tangtiang K; Piyawang W; Bhamarapravatana K
J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S121-5. PubMed ID: 26387399
[TBL] [Abstract][Full Text] [Related]
9. HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports.
Arfi A; Hequet D; Bataillon G; Tran-Perennou C; Farkhondeh F; Sastre-Garau X; Fourchotte V; Rouzier R; Laas E; Pouget N; Vincent-Salomon A; Jeannot E
BMC Cancer; 2019 Apr; 19(1):375. PubMed ID: 31014281
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
[TBL] [Abstract][Full Text] [Related]
11. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
[TBL] [Abstract][Full Text] [Related]
12. Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: a case report and review of the literature.
Nakamura F; Seino M; Suzuki Y; Sakaki H; Sudo T; Ohta T; Tsutsumi S; Nagase S
J Med Case Rep; 2019 Nov; 13(1):328. PubMed ID: 31699140
[TBL] [Abstract][Full Text] [Related]
13. Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy.
Silva NN; Eng C
J Adv Pract Oncol; 2012 May; 3(3):161-9. PubMed ID: 25031942
[TBL] [Abstract][Full Text] [Related]
14. Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311).
Ishikawa M; Shibata T; Kataoka T; Takekuma M; Kobayashi H; Yaegashi N; Satoh T;
Int J Gynecol Cancer; 2023 May; 33(5):692-700. PubMed ID: 36997229
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.
Greco FA; Burris HA; Litchy S; Barton JH; Bradof JE; Richards P; Scullin DC; Erland JB; Morrissey LH; Hainsworth JD
J Clin Oncol; 2002 Mar; 20(6):1651-6. PubMed ID: 11896116
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311).
Ishikawa M; Nakamura K; Shibata T; Tanaka K; Kitagawa R; Kobayashi H; Yaegashi N;
Jpn J Clin Oncol; 2018 Dec; 48(12):1096-1100. PubMed ID: 30295796
[TBL] [Abstract][Full Text] [Related]
18. Utility of UV Signature Mutations in the Diagnostic Assessment of Metastatic Head and Neck Carcinomas of Unknown Primary.
Furlan KC; Saeed-Vafa D; Mathew TM; Saller JJ; Tabbara SO; Boyle TA; Wenig BM; Hernandez-Prera JC
Head Neck Pathol; 2024 Feb; 18(1):11. PubMed ID: 38393464
[TBL] [Abstract][Full Text] [Related]
19. A case of refractory pelvic squamous cell carcinoma of unknown primary that responded to nivolumab.
Komura A; Taguchi A; Ikemura M; Nishijima A; Miyamoto Y; Tanikawa M; Sone K; Mori M; Oda K; Osuga Y
J Obstet Gynaecol Res; 2023 Apr; 49(4):1300-1304. PubMed ID: 36605009
[TBL] [Abstract][Full Text] [Related]
20. Unusual presentation of HPV-positive squamous cell carcinoma of the nasolacrimal duct as carcinoma of unknown primary.
Mokhtari TE; Warinner C; Edwards H; Chan AW; Annino D; Schoenfeld JD; Sethi RKV; Rettig EM
Am J Otolaryngol; 2022; 43(3):103457. PubMed ID: 35453094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
